Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Arzerra[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
2Arzerra - 100 MG - concentrato PER soluzione PER infusione - USO endovenoso - flacone(vetro) - 5 ML(20MG/ML) 3 flaconi[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
3Arzerra - 1000 MG - concentrato PER soluzione PER infusione - USO endovenoso - flaconcino (vetro) - 50 ML (20 MG/ML) 1 flaconcino + 2 KIT DI prolunga[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
4Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
(Arzerra, ARZERRA)		----[1] 13 💬
5Natalizumab/natalizumab-sztn, alemtuzumab, ocrelizumab, rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, cladribine, ofatumumab, ublituximab-xiiy, ocrelizumab and hyaluronidase-ocsq
(Arzerra, ARZERRA)		[1] Natalizumab[1] Natalizumab 💬 [1] ITGA4 💬 [15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬[1] 13 💬
6Ofatumumab
(Arzerra, ARZERRA)		[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[4] 11, 13, 35, 46 💬
7Ofatumumab 100
(Arzerra, ARZERRA)		[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
8Ofatumumab 300
(Arzerra, ARZERRA)		[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
9Ofatumumab 30MG
(Arzerra, ARZERRA)		[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
10Ofatumumab 3MG
(Arzerra, ARZERRA)		[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
11Ofatumumab 60MG
(Arzerra, ARZERRA)		[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
12Ofatumumab 700
(Arzerra, ARZERRA)		[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
13Ofatumumab approved dose
(Arzerra, ARZERRA)		[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
14Ofatumumab NEW dose
(Arzerra, ARZERRA)		[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
15Ofatumumab subcutaneous injection
(Arzerra, ARZERRA)		[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[2] 13, 35 💬
16Ofatumumab with AI
(Arzerra, ARZERRA)		[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
17Ofatumumab with PRF
(Arzerra, ARZERRA)		[1] Ofatumumab[1] Ofatumumab (Arzerra, ARZERRA) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬